Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss Inflammatory Bowel Disease Cohort

Inflammatory Bowel Diseases

Volumn 21, Issue 8, 2015, Pages 1794-1800

  Vavricka, Stephan R ^a,b   Rogler, Gerhard ^a   Gantenbein, Claudine ^a   Spoerri, Muriel ^a   Vavricka, Mareike Prinz ^c   Navarini, Alexander A ^d,e   French, Lars E ^d   Safroneeva, Ekaterina ^f   Fournier, Nicolas ^g   Straumann, Alex ^h   Froehlich, Florian ^h   Fried, Michael ^a   Michetti, Pierre ^i,j   Seibold, Frank ^k   Lakatos, Peter L ^j   Peyrin Biroulet, Laurent ^l   Schoepfer, Alain M ^m  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

^c Private Practice   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF BERN   (Switzerland)

^g UNIVERSITY OF LAUSANNE   (Switzerland)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ Crohn and Colitis Center   (Switzerland)

^j SEMMELWEIS UNIVERSITY   (Hungary)

^k Spital Netz Bern   (Switzerland)

^l CHU NANCY BRABOIS   (France)

^m LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

more..

Author keywords

Arthritis; Extraintestinal manifestations; Inflammatory bowel disease; Uveitis

Indexed keywords

ADULT; ANKYLOSING SPONDYLITIS; APHTHOUS STOMATITIS; ARTHRITIS; ARTHROPATHY; ARTICLE; COHORT ANALYSIS; COLITIS; CROHN DISEASE; DISEASE DURATION; ENTEROPATHY; ERYTHEMA NODOSUM; EXTRAINTESTINAL MANIFESTATION; FEMALE; HUMAN; INDETERMINATE COLITIS; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL ARTHRITIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PSORIASIS; PYODERMA GANGRENOSUM; SURVIVAL RATE; ULCERATIVE COLITIS; UVEITIS; ADOLESCENT; AGED; COMPLICATION; FOLLOW UP; MIDDLE AGED; PROGNOSIS; SPONDYLITIS, ANKYLOSING; STOMATITIS, APHTHOUS; SWITZERLAND; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS; COHORT STUDIES; ERYTHEMA NODOSUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROGNOSIS; PYODERMA GANGRENOSUM; SPONDYLITIS, ANKYLOSING; STOMATITIS, APHTHOUS; SWITZERLAND; TIME FACTORS; YOUNG ADULT;

EID: 84946918299     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000429     Document Type: Article

References (30)

1. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129:827-836.
2. Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116-1122.
3. Mendoza JL, Lana R, Taxonera C, et al. Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis (in Spanish). Med Clin (Barc). 2005;125:297-300.
4. Ricart E, Panaccione R, Loftus EV Jr, et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2004;10:207-214.
5. Rankin GB, Watts HD, Melnyk CS, et al. National Cooperative Crohn's disease study: extraintestinal manifestations and perianal complications. Gastroenterology. 1979:77:914-920.
6. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:307-327.
7. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23:29-34.
8. Vavricka SR, Brun L, Ballabeni PL, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss Inflammatory Bowel Disease Cohort. Am J Gastroenterol. 2011;106:110-119.
9. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci. 1999;44:1-13.
10. Monsén U, Sorstad J, Hellers G, et al. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol. 1990;85:711-716.
11. Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11:7227-7236.
12. Kethu SR. Extraintestinal manifestations of inflammatory bowel diseases. J Clin Gastroenterol. 2006;40:467-475.
13. Trost LB, McDonnell JK: Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J. 2005;81: 580-585.
14. Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2007;13: 1424-1429.
15. Levitt M, Ritchie J, Lennard-Jones J, et al. Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg. 1991;78: 676-678.
16. Mir-Madjlessi SH, Taylor JS, Farmer RG. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol. 1985;80: 615-620.
17. Vavricka SR, Spigaglia SM, Rogler G, et al. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:496-505.
18. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis. 2010;4:7-27.
19. Stange EF, Travis SPL, Vermeire S, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008;2:1-23.
20. Pittet V, Juillerat P, Mottet C, et al. Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol. 2009;38:922-931.
21. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol. 2003;48:805-821.
22. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol. 2009;23:561-565.
23. Nair R, Henseler T, Jenisch S, et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet. 1997;6:1349-1356.
24. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
25. Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol. 2003;9:2300-2307.
26. Schoepfer AM, Dehlavi A, Fournier N, et al. Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol. 2013;108:1744-1753.
27. Ardizzone S, Puttini PS, Cassinotti A, et al. Extraintestinal manifestations of inflammatory bowel disease. Dig Liv Dis. 2008;40(suppl 2):S253-S259.
28. Bhagat S, Das KM. A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology. 1994;107:103-108.
29. Chapman RW, Varghese Z, Gaul R, et al. Association of primary sclerosing cholangitis with HLA-B8. Gut. 1983;24:38-41.
30. Roussomoustakaki M, Satsangi J, Welsh K, et al. Genetic markers may predict disease behaviour in patients with ulcerative colitis. Gastroenterology. 1997;112:1845-1853.